{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/qualified-infectious-disease-product-designation-whats-gain#webpage",
"url": "https://www.fortrea.com/insights/qualified-infectious-disease-product-designation-whats-gain",
"name": "Qualified infectious disease product designation: What's to GAIN?",
"description": "Explore this Fortrea white paper on Qualified Infectious Disease Product (QIDP) designation strategies and discover how the GAIN Act is supporting infectious disease drug development through expedited regulatory pathways and development incentives for therapies targeting serious and life-threatening infections. The white paper examines the growing impact of antimicrobial resistance on global healthcare and explores how QIDP designation can help sponsors accelerate antibacterial and antifungal drug development through regulatory advantages such as Fast Track eligibility, Priority Review opportunities, and extended market exclusivity. Learn how infectious disease regulatory strategy, anti-infective clinical development planning, FDA pathway optimization, and evidence generation approaches are helping organizations navigate the evolving infectious disease landscape while advancing therapies for multidrug-resistant pathogens, hospital-acquired infections, and other critical infectious disease challenges"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Qualified infectious disease product designation: What's to GAIN?",
"item": "https://www.fortrea.com/insights/qualified-infectious-disease-product-designation-whats-gain"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/qualified-infectious-disease-product-designation-whats-gain#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/qualified-infectious-disease-product-designation-whats-gain#webpage"
},
"headline": "Qualified Infectious Disease Product (QIDP) Designation & GAIN Act Strategies | Fortrea White Paper",
"description": "Explore this Fortrea white paper on Qualified Infectious Disease Product (QIDP) designation strategies and discover how the GAIN Act is supporting infectious disease drug development through expedited regulatory pathways and development incentives for therapies targeting serious and life-threatening infections. The white paper examines the growing impact of antimicrobial resistance on global healthcare and explores how QIDP designation can help sponsors accelerate antibacterial and antifungal drug development through regulatory advantages such as Fast Track eligibility, Priority Review opportunities, and extended market exclusivity. Learn how infectious disease regulatory strategy, anti-infective clinical development planning, FDA pathway optimization, and evidence generation approaches are helping organizations navigate the evolving infectious disease landscape while advancing therapies for multidrug-resistant pathogens, hospital-acquired infections, and other critical infectious disease challenges",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/qualified-infectious-disease-product-designation.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-10",
"dateModified": "2025-02-10",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/WP_0057_Neuro%20Patient%20Centric_0624_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}